Chamuleau, M. (2022) R-CODOX-M/R-IVAC versus Dose-Adjusted (DA)-EPO-CH-R in Patients with Newly Diagnosed High-Risk Burkitt Lymphoma; First Results of a Multi-Center Randomized Hovon/Sakk Trial [Abstract LB2370]. Proceedings of the European Hematology Association Congress EHA2022, Vienna, 9-12 June 2022.

has been cited by the following article:

• TITLE: Burkitt Lymphoma Presenting as Ileocolic Intussusception in an Adult

  AUTHORS: Carla Isabel Borré, Bethany Boyle, Kelsey Lynch, Anuradha Kanaparthi, Clifford Michael Csizmar, Daniel Philip Larson, Matthew Dain Braithwaite, Isla McKerrow Johnson, Thomas Elmer Witzig, Diego Armando Suarez

  KEYWORDS: Burkitt Lymphoma, Adult Intussusception, Prognostication

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.13 No.4, December 8, 2023

  ABSTRACT: Adult intussusception is rare, highly associated with a malignant lead point, and often requires emergent surgical management. We report the case of a 44-year-old male who presented with generalized abdominal pain and was found to have early ileocolic intussusception secondary to a large ileocecal mass. Biopsies of the mass and an enlarged cardiophrenic lymph node, as well as pleural fluid cytology were all consistent with Burkitt lymphoma (BL). Curiously, the patient’s abdominal exam was reassuring, and the intussusception and malignant bowel obstruction resolved over 36 hours with conservative management alone. With a Burkitt lymphoma international prognostic index (BL-IPI) score of 2, the patient proceeded to treatment with combination chemoimmunotherapy and attained a complete response after four cycles. There was no bowel perforation or recurrent intussusception throughout treatment. Thus, this report marks the first reported case of adult BL-associated intussusception to resolve with non-invasive management and establishes a precedent for conservative management in select patients.